FY2026 Earnings Estimate for OCUL Issued By HC Wainwright

Ocular Therapeutix, Inc. (NASDAQ:OCUL) – Research analysts at HC Wainwright issued their FY2026 earnings per share estimates for shares of Ocular Therapeutix in a research note issued to investors on Tuesday, May 6th. HC Wainwright analyst Y. Chen forecasts that the biopharmaceutical company will post earnings of ($1.46) per share for the year. HC Wainwright currently has a “Buy” rating and a $15.00 target price on the stock. The consensus estimate for Ocular Therapeutix’s current full-year earnings is ($0.98) per share.

Ocular Therapeutix (NASDAQ:OCUL) last released its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.05). Ocular Therapeutix had a negative net margin of 283.74% and a negative return on equity of 45.18%. The company had revenue of $17.08 million for the quarter, compared to analysts’ expectations of $16.89 million.

OCUL has been the subject of a number of other reports. William Blair initiated coverage on shares of Ocular Therapeutix in a report on Tuesday, April 8th. They set an “outperform” rating for the company. Royal Bank of Canada assumed coverage on Ocular Therapeutix in a report on Tuesday, March 18th. They issued an “outperform” rating and a $17.00 price objective for the company. Needham & Company LLC reduced their target price on Ocular Therapeutix from $15.00 to $14.00 and set a “buy” rating on the stock in a research note on Tuesday. Finally, JMP Securities set a $19.00 price target on Ocular Therapeutix in a research note on Tuesday, March 4th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, Ocular Therapeutix currently has an average rating of “Moderate Buy” and an average target price of $16.25.

Ocular Therapeutix Trading Up 5.6 %

Shares of OCUL opened at $7.45 on Wednesday. The stock has a market capitalization of $1.19 billion, a P/E ratio of -5.64 and a beta of 1.51. Ocular Therapeutix has a twelve month low of $4.79 and a twelve month high of $11.78. The company has a quick ratio of 12.94, a current ratio of 13.01 and a debt-to-equity ratio of 0.19. The firm has a fifty day simple moving average of $7.45 and a two-hundred day simple moving average of $8.32.

Insider Transactions at Ocular Therapeutix

In related news, insider Pravin Dugel sold 21,475 shares of the business’s stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $6.87, for a total transaction of $147,533.25. Following the sale, the insider now owns 3,520,318 shares of the company’s stock, valued at $24,184,584.66. The trade was a 0.61 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 3.50% of the company’s stock.

Hedge Funds Weigh In On Ocular Therapeutix

Several large investors have recently made changes to their positions in OCUL. Point72 Asset Management L.P. increased its position in Ocular Therapeutix by 43.9% during the 4th quarter. Point72 Asset Management L.P. now owns 2,935,924 shares of the biopharmaceutical company’s stock valued at $25,073,000 after buying an additional 895,304 shares in the last quarter. Peregrine Capital Management LLC bought a new position in shares of Ocular Therapeutix during the first quarter valued at $6,212,000. Millennium Management LLC bought a new position in Ocular Therapeutix in the 4th quarter worth about $3,819,000. Assenagon Asset Management S.A. purchased a new stake in Ocular Therapeutix during the 1st quarter valued at about $2,505,000. Finally, Artisan Partners Limited Partnership increased its stake in Ocular Therapeutix by 26.4% during the 4th quarter. Artisan Partners Limited Partnership now owns 1,334,702 shares of the biopharmaceutical company’s stock valued at $11,398,000 after purchasing an additional 278,610 shares in the last quarter. 59.21% of the stock is currently owned by hedge funds and other institutional investors.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.